alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
| **SECURITIES AND EXCHANGE COMMISSION** |
|----------------------------------------|

| **Washington, D.C. 20549** |
|----------------------------|

| **FORM 6-K** |
|--------------|

| **REPORT OF FOREIGN ISSUER      PURSUANT TO RULE 13a-16 OR 15b-16 OF      THE SECURITIES EXCHANGE ACT OF 1934** |
|-----------------------------------------------------------------------------------------------------------------|

| For December 31, 2002 |
|-----------------------|

| Distribution and Service D&S, Inc. |
|----------------------------------------|

| (Translation of registrant’s name into English) |
|------------------------------------------------------|

| Distribución y Servicio D&S S.A.      Avenida Presidente Eduardo Frei Montalva 8301 |
|------------------------------------------------------------------------------------------------|

| Quilicura Santiago Chile (Address of principal executive offices) |
|-------------------------------------------------------------------|

| Form 20-F |X| Form 40-F |_| |
|----------------------------------|

|      Indicate by check mark whether      the registrant by furnishing the information contained in this Form is also      thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)      under the Securities Exchange Act of 1934. |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Yes |_| No |X| |
|----------------|

|   |  |   |
|--------|--|--------|
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1710 Total triiodothyronine test system. ( a ) *Identification.* A total triiodothyronine test system is a device intended to measure the hormone triiodothyronine in serum and plasma. Measurements obtained by this device are used in the diagnosis and treatment of thyroid diseases such as hyperthyroidism.
( b ) *Classification.* Class II. This device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 62286, Oct. 18, 2000]
§ 74.2336 D&C Red No. 36. ( a ) *Identity and specifications.* The color additive D&C Red No. 36 shall conform in identity and specifications to the requirements of § 74.1336 (a)(1) and (b).
( b ) *Uses and restrictions.* The color additive D&C Red No. 36 may be safely used for coloring cosmetic lip products in amounts not to exceed 3 percent total color by weight of the finished cosmetic products. D&C Red No. 36 may be safely used for coloring externally applied cosmetics in amounts consistent with current good manufacturing practice.
( c ) *Labeling requirements.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( d ) *Certification.* All batches of D&C Red No. 36 shall be certified in accordance with regulations in part 80 of this chapter.
[53 FR 29031, Aug. 2, 1988]
# C_2018328EN.01003901.xml

| 17.9.2018 | EN | Official Journal of the European Union | C 328/39 |
| --- | --- | --- | --- |

17.9.2018

EN

Official Journal of the European Union

C 328/39

---

Judgment of the General Court of 12 July 2018 — Fujikura v Commission

(Case T-451/14) (1)

((Competition - Agreements, decisions and concerted practices - European market for power cables - Decision finding an infringement of Article 101 TFEU - Single and continuous infringement - Proof of the infringement - Duration of participation - Calculation of the fine - Gravity of the infringement - Unlimited jurisdiction))

(2018/C 328/53)

Language of the case: English

Parties

Applicant: Fujikura Ltd (Tokyo, Japan) (represented by L. Gyselen, lawyer)

Defendant: European Commission (represented by A. Biolan, C. Giolito and H. van Vliet, acting as Agents, and by M. Johansson, lawyer)

Intervener in support of the applicant: Viscas Corp. (Tokyo) (represented by J.-F. Bellis, lawyer)

Re:

Action pursuant to Article 263 TFEU for annulment of Commission Decision C(2014) 2139 final of 2 April 2014 relating to a proceeding under Article 101 [TFEU] and Article 53 of the EEA Agreement (Case AT.39610 — Power cables) in so far as it concerns the applicant and, in the alternative, an application for a reduction of the fine imposed on the applicant in that decision.

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Fujikura Ltd to bear its own costs and to pay those of the European Commission; |
| --- | --- |

2.

Orders Fujikura Ltd to bear its own costs and to pay those of the European Commission;

| 3. | Orders Viscas Corp. to bear its own costs. |
| --- | --- |

3.

Orders Viscas Corp. to bear its own costs.

---

(1)  OJ C 303, 8.9.2014.

---
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THE SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM FORM 10Q FOR
THE QUARTER ENDED SEPTEMBER 31, 1997 AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINACIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                         270,957
<SECURITIES>                                         0
<RECEIVABLES>                                3,754,242
<ALLOWANCES>                                   399,000
<INVENTORY>                                  2,489,335
<CURRENT-ASSETS>                             6,297,978
<PP&E>                                      10,391,168
<DEPRECIATION>                               4,176,364
<TOTAL-ASSETS>                              13,165,039
<CURRENT-LIABILITIES>                        6,123,900
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           415
<OTHER-SE>                                   3,954,553
<TOTAL-LIABILITY-AND-EQUITY>                13,165,039
<SALES>                                      9,613,518
<TOTAL-REVENUES>                             9,613,518
<CGS>                                        9,430,643
<TOTAL-COSTS>                                9,430,643
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           1,069,105
<INCOME-PRETAX>                            (7,063,569)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (7,063,569)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (7,063,569)
<EPS-PRIMARY>                                   (0.19)
<EPS-DILUTED>                                   (0.19)
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3250 *Erysipelothrix rhusiopathiae* serological reagents. ( a ) *Identification. Erysipelothrix rhusiopathiae* serological reagents are devices that consist of antigens and antisera used in serological tests to identify *Erysipelothrix rhusiopathiae* from cultured isolates derived from clinical specimens. The identification aids in the diagnosis of disease caused by this bacterium belonging to the genus *Erysipelothrix.* This organism is responsible for a variety of inflammations of the skin following skin abrasions from contact with fish, shellfish, or poultry.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 54 FR 25046, June 12, 1989; 66 FR 38791, July 25, 2001]
Exhibit 10.11(b)


HORACE MANN SERVICE CORPORATION


EXECUTIVE SEVERANCE PLAN


 


SCHEDULE A PARTICIPANTS


 


	NAME OR TITLE	 	EFFECTIVE DATE OF
	 	 	PARTICIPATION*
	 	 	 
	 	TIER I PARTICIPANTS	 
	President and CEO	 	May 16, 2013
	 	 	 
	 	TIER II PARTICIPANTS	 
	EVP, Life & Retirement	 	March 22, 2012
	EVP, Property & Casualty	 	July 1, 2015
	 	 	 
	 	TIER III PARTICIPANTS	 
	SVP, Field Operations and Distribution	 	August 13, 2015**
	SVP and Controller/Acting CFO	 	***


 


*Subject to acceptance within 30 days of
effective date of participation.


**On April 13, 2017, the Company announced
that Kelly Stacy, head of field operations, is leaving the Company effective April 21, 2017. Mr. Stacy’s current responsibilities
will be absorbed by existing members of the management team.


***Designates an individual who, as of
the Effective Date of Participation, is covered by a Severance Agreement, as defined in Section 4.3(c)(i) of the Plan.


 


Last updated: February 3, 2017
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3240 Equine encephalomyelitis virus serological reagents. ( a ) *Identification.* Equine encephalomyelitis virus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antobodies to equine encephalomyelitis virus in serum. The identification aids in the diagnosis of diseases caused by equine encephalomyelitis viruses and provides epidemiological information on these viruses. Equine encephalomyelitis viruses are transmitted to humans by the bite of insects, such as mosquitos and ticks, and may cause encephalitis (inflammation of the brain), rash, acute arthritis, or hepatitis.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 65 FR 2311, Jan. 14, 2000]
Fourth Court of Appeals

San Antonio, Texas

November 19, 2015

No. 04-15-00717-CV

IN THE ESTATE OF MARIA L. RAYNES,

From the Probate Court No 1, Bexar County, Texas

Trial Court No. 2013-PC-0369

Honorable Kelly Cross, Judge Presiding

ORDER

The Appellant’s Motion to Transfer Reporter’s Record is GRANTED.

_________________________________

Sandee Bryan Marion, Chief Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 19th day of November, 2015.

___________________________________

Keith E. Hottle

Clerk of Court
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.5240 Automated blood cell diluting apparatus. ( a ) *Identification.* An automated blood cell diluting apparatus is a fully automated or semi-automated device used to make appropriate dilutions of a blood sample for further testing.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 864.9.
[45 FR 60596, Sept. 12, 1980, as amended at 65 FR 2310, Jan. 14, 2000]
Exhibit 23

 

**Consent of Independent Registered Public Accounting Firm**

 

Weconsent to the incorporation by reference in the Registration Statements on Form S-8(No. 333-155875 and 333-130041)****of RetractableTechnologies, Inc. of our report dated March 31, 2009 relating to ouraudit of the financial statements and financial statement schedule, whichappear in this Annual Report on Form 10-K of Retractable Technologies, Inc.for the year ended December 31, 2008.

 
|   | /s/  CF & Co., L.L.P. |
|--------|--------------------------------|
|   | CF &  Co., L.L.P.     |

 

Dallas,Texas

March 31,2009
# C_2014052EN.01005003.xml

| 22.2.2014 | EN | Official Journal of the European Union | C 52/50 |
| --- | --- | --- | --- |

22.2.2014

EN

Official Journal of the European Union

C 52/50

---

Action brought on 2 January 2014 — Anudal v Commission

(Case T-5/14)

2014/C 52/98

Language of the case: Spanish

Parties

Parties

Applicant: Anudal, SL (Badalona, Spain) (represented by: J. García Muñoz, J. Jiménez-Blanco and J. Corral García, lawyers)

Applicant:

Defendant: European Commission

Defendant:

Form of order sought

Form of order sought

The applicant claims that the General Court should:

| — | annul Articles 1 to 6 of the Decision; |
| --- | --- |

—

annul Articles 1 to 6 of the Decision;

| — | in the alternative, annul Article 4 of the Decision, in so far as it orders recovery of the aid; and |
| --- | --- |

—

in the alternative, annul Article 4 of the Decision, in so far as it orders recovery of the aid; and

| — | order the Commission to pay all the costs arising from these proceedings. |
| --- | --- |

—

order the Commission to pay all the costs arising from these proceedings.

Pleas in law and main arguments

Pleas in law and main arguments

The pleas in law and main arguments are those put forward in Case T-3/14 Anudal Industrial v Commission.

Anudal Industrial

Commission

---
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JUL-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                         133,452
<SECURITIES>                                         0
<RECEIVABLES>                                   55,381
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               271,676
<PP&E>                                         162,113
<DEPRECIATION>                                (143,175)
<TOTAL-ASSETS>                                 529,886
<CURRENT-LIABILITIES>                          340,135
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        14,529
<OTHER-SE>                                  (1,478,022)
<TOTAL-LIABILITY-AND-EQUITY>                   529,886
<SALES>                                        135,588
<TOTAL-REVENUES>                               135,588
<CGS>                                           38,101
<TOTAL-COSTS>                                   38,101
<OTHER-EXPENSES>                              (485,532)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             (10,142)
<INCOME-PRETAX>                               (377,903)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (377,903)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (377,903)
<EPS-BASIC>                                       (.03)
<EPS-DILUTED>                                     (.03)


</TABLE>
IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 15-41174

Summary Calendar

UNITED STATES OF AMERICA,

Plaintiff-Appellee

v.

ANDRE DONNELL ROUTT,

Defendant-Appellant

Appeal from the United States District Court

for the Eastern District of Texas

USDC No. 1:94-CR-12

Before KING, CLEMENT, and OWEN, Circuit Judges.

PER CURIAM:*

Andre Donnell Routt, federal prisoner # 60985-079, appeals the denial of 

his motion to reduce his sentence under 18 U.S.C. § 3582(c)(2) based on 

Amendment 782 to the Sentencing Guidelines. Routt contends that he was 

entitled to a two-level reduction of his base offense level under Amendment 

782 and that, as a result, his new base offense level would be 36.

 

* Pursuant to 5TH CIR. R. 47.5, the court has determined that this opinion should not 

be published and is not precedent except under the limited circumstances set forth in 5TH 

CIR. R. 47.5.4.

United States Court of Appeals

Fifth Circuit

FILED

April 1, 2016

Lyle W. Cayce

Clerk

 Case: 15-41174 Document: 00513448417 Page: 1 Date Filed: 04/01/2016
No. 15-41174

2

The record confirms that Routt was ineligible for a sentence reduction 

under § 3582(c)(2) because Amendment 782 did not lower his base offense level. 

Routt fails to acknowledge that he was held responsible for 42.5 kilograms and 

four ounces of crack cocaine and 150 kilograms of powder cocaine. Under the 

retroactive, amended version of U.S.S.G. § 2D1.1(c)(1), which has now taken 

effect, Routt has a base offense level of 38 because he was responsible for the 

equivalent of more than 90,000 kilograms of marijuana. See § 2D1.1(c)(1) 

(2015). His specific offense level enhancements added six more levels. Routt’s 

total offense level of 44, together with a criminal history category of IV, results 

in a guidelines range of life imprisonment. See U.S.S.G. Ch. 5, Pt. A. Because

Amendment 782 did not reduce Routt’s sentencing range, the district court 

properly found that he was ineligible for relief under § 3582(c)(2). See U.S.S.G. 

§ 1B1.10(a)(2)(B) & comment. (n.1(A)); Dillon v. United States, 560 U.S. 817, 

826 (2010).

The judgment of the district court is AFFIRMED.

 Case: 15-41174 Document: 00513448417 Page: 2 Date Filed: 04/01/2016
Exhibit 99.2

# Section 906
Certification

# CERTIFICATION OF
PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350

In
connection with the accompanying Annual Report on Form 20-F of NUR Macroprinters Ltd. for
the year ended December 31, 2002, I, Hilel E. Kremer, the principal financial officer of
The A Consulting Team, Inc., hereby certify pursuant to 18 U.S.C. § 1350, as adopted
pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

| | (1)
                                       such Annual Report on Form 20-F for the year ended
December 31, 2002 fully                     complies with the requirements of Section
13(a) or 15(d) of the Securities                     Exchange Act of 1934; and
| | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | (2)
                                       the information contained in such Annual Report on
Form 20-F for the year ended                     December 31, 2002 fairly presents, in
all material respects, the financial                     condition and results of
operations of NUR Macroprinters Ltd.
| | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|May 15, 2003
____________________________________
Date | /S/ Hilel E. Kremer
____________________________________
Hilel E. Kremer
Chief Financial Officer
|------------------------------------------------------ | ------------------------------------------------------------------------------------------------

A signed original of this written
statement required by section 906 has been provided to the Company and will be retained by
the Company and furnished to the Securities and Exchange Commission or its staff upon
request.

The Foregoing certification is being
furnished solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections
(a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being
filed as part of the Form 20F or as a separate disclosure document.



---

---
# C_2014329EN.01001601.xml

| 22.9.2014 | EN | Official Journal of the European Union | C 329/16 |
| --- | --- | --- | --- |

22.9.2014

EN

Official Journal of the European Union

C 329/16

---

Order of the President of the General Court of 10 June 2014 — Friedrich Wilhelms-Hütte Eisenguss v Commission

(Case T-178/14 R)

((Interim measures - State aid - National promotion of electricity production from a renewable source - Commission decision to open formal investigation procedure into State aid - Application for suspension of operation of a measure - Urgency - Fumus boni juris))

2014/C 329/21

Language of the case: German

Parties

Parties

Applicant: Friedrich Wilhelms-Hütte Eisenguss GmbH (Mullheim an der Ruhr, Germany) (represented by: H. Hofler, C. Kahle and V. Winkler, lawyers)

Applicant:

Defendant: European Commission (represented by: T. Maxian Rusche and R. Sauer, Agents)

Defendant:

Re:

Re:

Application for suspension of the legal effects of the decision by which the Commission opened a formal investigation procedure in respect of State aid concerning the German law on renewable energy.

Operative part of the order

Operative part of the order

| 1. | The application for interim measures is dismissed. |
| --- | --- |

1.

The application for interim measures is dismissed.

| 2. | The judgment in Case T-178/14 R Friedrich Wilhelms-Hütte Eisenguss v Commission is set aside. |
| --- | --- |

2.

The judgment in Case T-178/14 R Friedrich Wilhelms-Hütte Eisenguss v Commission is set aside.

| 3. | Costs are reserved. |
| --- | --- |

3.

Costs are reserved.

---
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.2800 Animal and human sera. ( a ) *Identification.* Animal and human sera are biological products, obtained from the blood of humans or other animals, that provide the necessary growth-promoting nutrients in a cell culture system.
( b ) *Classification.* Class I (general controls). These devices are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
[45 FR 60586, Sept. 12, 1980, as amended at 54 FR 25044, June 12, 1989; 66 FR 38789, July 25, 2001]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1020 Acid phosphatase (total or prostatic) test system. ( a ) *Identification.* An acid phosphatase (total or prostatic) test system is a device intended to measure the activity of the acid phosphatase enzyme in plasma and serum.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 84 FR 71796, Dec. 30, 2019]
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.8200 Blood cell diluent. ( a ) *Identification.* A blood cell diluent is a device used to dilute blood for further testing, such as blood cell counting.
( b ) *Classification.* Class I (general controls). This device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
[45 FR 60635, Sept. 12, 1980, as amended at 54 FR 25045, June 12, 1989; 66 FR 38790, July 25, 2001]